0001729149-26-000009
SEC filingViemed Healthcare, Inc. reported strong financial performance for fiscal year 2025, with revenue increasing to $270.3 million from $224.3 million in 2024, representing year-over-year growth. Gross profit rose to $155.5 million, and net income attributable to Viemed reached $14.9 million. The company generated $51.9 million in net cash from operating activities, which supported significant investments including $40.0 million in property and equipment purchases and $26.3 million in acquisitions. Key revenue drivers included ventilator rentals, which accounted for approximately 51% of total revenue, and Medicare/Medicaid reimbursement, which represented 40% of revenue. The company maintained a solid balance sheet with total assets of $199.2 million and shareholders' equity of $143.5 million. Forward-looking significance includes expansion through acquisitions, continued focus on home-based healthcare services, and navigating evolving regulatory environments including Medicare coverage determinations.
Viemed Healthcare, Inc. delivered strong financial results for fiscal year 2025, with revenue increasing to $270.3 million from $224.3 million in 2024, representing 20.5% year-over-year growth. Gross profit grew to $155.5 million from $133.2 million in the prior year, while operating income improved to $22.9 million from $17.9 million. Net income attributable to Viemed reached $14.9 million, up from $11.3 million in 2024. The company maintained solid profitability metrics with a gross margin of 57.5% and operating margin of 8.5%. Basic earnings per share increased to $0.38 from $0.29 in the prior year. These results reflect continued execution of the company's growth strategy through both organic expansion and strategic acquisitions.
Revenue growth was driven by multiple factors, with ventilator rentals (non-invasive and invasive) representing $136.7 million or approximately 51% of total revenue. Other home medical equipment rentals contributed $58.4 million, while equipment and supply sales generated $50.3 million, and service revenues added $24.9 million. The company's revenue mix showed continued diversification beyond its core ventilator business. Medicare and Medicaid reimbursement accounted for 40% of total revenue in 2025, down from 43% in 2024, indicating some diversification in payor mix. The company serves patients in all 50 states and has expanded its service offerings to include women's health products and healthcare staffing services alongside its core respiratory care business.
Gross margin decreased slightly to 57.5% in 2025 from 59.4% in 2024, reflecting changes in revenue mix and potentially higher equipment costs. Operating margin improved to 8.5% from 8.0% in the prior year, demonstrating effective cost management despite increased selling, general and administrative expenses of $121.4 million. Research and development expenses remained relatively stable at $3.0 million. Stock-based compensation increased to $9.1 million from $6.3 million in 2024, reflecting expanded equity compensation programs. The company maintained disciplined expense management while investing in growth initiatives, resulting in improved operating leverage as revenue growth outpaced expense increases.
The company generated strong operating cash flow of $51.9 million, which funded significant investing activities including $40.0 million in property and equipment purchases and $26.3 million in acquisitions. Free cash flow (operating cash flow minus capital expenditures) was $1.8 million. The balance sheet remained healthy with total assets of $199.2 million, including $48.5 million in current assets and $150.7 million in long-term assets. Property and equipment, net stood at $78.8 million, while goodwill increased to $58.9 million primarily due to acquisitions. Total liabilities were $55.6 million, with long-term debt of $11.3 million. Shareholders' equity reached $143.5 million, providing a solid capital base for continued growth.
The company's strategic priorities include continued expansion through acquisitions, as evidenced by the $26.3 million spent on acquisitions in 2025. Management anticipates growth opportunities from the continued trend of servicing patients in the home rather than in hospitals. However, the company faces regulatory risks including evolving Medicare coverage determinations, particularly for non-invasive positive pressure ventilation for COPD treatment. The competitive bidding process for durable medical equipment remains a consideration, though current product categories are not included in the next round. The company must also navigate accreditation requirements that will become more frequent beginning in 2027. Viemed expects to continue leveraging its technology-enabled, home-based clinical care model to drive growth while managing regulatory compliance and reimbursement challenges.